(Q38307583)

2 September 2017

1 reference

title

Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension (English)

1 reference

2 September 2017

1

Gillian M Keating

1 reference

2 September 2017

publication date

1 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

75

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

197-206

1 reference

Management of neurogenic orthostatic hypotension in patients with autonomic failure

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Norepinephrine precursor therapy in neurogenic orthostatic hypotension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

Drug treatment of orthostatic hypotension because of autonomic failure or neurocardiogenic syncope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

L-threo-DOPS treatment of orthostatic hypotension in Swedish patients with familial amyloidotic polyneuropathy (TTR-met30)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40265-014-0342-1

The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors

21 January 2018

1 reference

12 December 2020

The treatment of orthostatic hypotension with dihydroxyphenylserine

1 reference

12 December 2020

Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).

1 reference

12 December 2020

The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale

1 reference

12 December 2020

Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).

1 reference

12 December 2020

A practical guide to the treatment of neurogenic orthostatic hypotension

1 reference

12 December 2020

10.1007/S40265-014-0342-1

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1014623908

0 references

1 reference